Pharmacodynamic and Antineoplastic Activity of BI 836845, a Fully Human IGF Ligand-Neutralizing Antibody, and Mechanistic Rationale for Combination with Rapamycin

Katrin Friedbichler(Boehringer Ingelheim (Germany)), Paul J. Adam(Boehringer Ingelheim (Austria))

Molecular Cancer Therapeutics

December 3, 2013

10.1158/1535-7163.mct-13-0598

Cited by 99

Related Papers

Supplementary Materials and Methods, Tables 1-2 and Figure Legends from Pharmacodynamic and Antineoplastic Activity of BI 836845, a Fully Human IGF Ligand-Neutralizing Antibody, and Mechanistic Rationale for Combination with Rapamycin

|Unknown|2023|0